2025 China Age-Related Mascular Degeneration Revenue Opportunities Report
Description
The 2025 China Age-Related Mascular Degeneration Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) market in China are Regeneron Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd, and Novartis AG. These multinational corporations lead treatment options for wet AMD, primarily through their anti-VEGF therapies such as Regeneron's high-dose aflibercept, Bayer’s Eylea (aflibercept), Roche’s Vabysmo (faricimab), and Novartis’s Beovu (brolucizumab), which are either approved or in advanced development phases in China. Chinese biopharma firms like Chengdu Kanghong Biotech and Innovent Biologics also play significant roles, focusing on biosimilars and novel treatments like conbercept (Chengdu Kanghong) and others entering late-stage clinical trials.
In addition to drug manufacturers, companies such as AffaMed Therapeutics are pioneering treatments for dry AMD, a subtype with limited current therapies in China, exemplified by the recent NMPA approval to conduct Phase III trials for Risuteganib, targeting intermediate dry AMD. Samsara Vision has introduced implantable miniature telescopes in China to enhance vision for late-stage AMD patients, marking technological innovation in ophthalmologic devices within the region. The AMD treatment landscape in China is evolving rapidly, with these four global leaders and emerging domestic firms driving advancements in both pharmacologic and device-based therapies amid an aging population with growing demand.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) market in China are Regeneron Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd, and Novartis AG. These multinational corporations lead treatment options for wet AMD, primarily through their anti-VEGF therapies such as Regeneron's high-dose aflibercept, Bayer’s Eylea (aflibercept), Roche’s Vabysmo (faricimab), and Novartis’s Beovu (brolucizumab), which are either approved or in advanced development phases in China. Chinese biopharma firms like Chengdu Kanghong Biotech and Innovent Biologics also play significant roles, focusing on biosimilars and novel treatments like conbercept (Chengdu Kanghong) and others entering late-stage clinical trials.
In addition to drug manufacturers, companies such as AffaMed Therapeutics are pioneering treatments for dry AMD, a subtype with limited current therapies in China, exemplified by the recent NMPA approval to conduct Phase III trials for Risuteganib, targeting intermediate dry AMD. Samsara Vision has introduced implantable miniature telescopes in China to enhance vision for late-stage AMD patients, marking technological innovation in ophthalmologic devices within the region. The AMD treatment landscape in China is evolving rapidly, with these four global leaders and emerging domestic firms driving advancements in both pharmacologic and device-based therapies amid an aging population with growing demand.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
